P
Peta-Anne Paul-Brent
Researcher at University of Queensland
Publications - 16
Citations - 298
Peta-Anne Paul-Brent is an academic researcher from University of Queensland. The author has contributed to research in topics: Aspirin & Placebo. The author has an hindex of 7, co-authored 16 publications receiving 211 citations. Previous affiliations of Peta-Anne Paul-Brent include Southern Cross University.
Papers
More filters
Journal ArticleDOI
Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis a randomized clinical trial
Ashley Irish,Ashley Irish,Andrea K. Viecelli,Andrea K. Viecelli,Carmel M. Hawley,Carmel M. Hawley,Lai Seong Hooi,Elaine M. Pascoe,Peta-Anne Paul-Brent,Sunil V. Badve,Sunil V. Badve,Sunil V. Badve,Trevor A. Mori,Alan Cass,Peter G. Kerr,David Voss,Loke Meng Ong,Kevan R. Polkinghorne +17 more
TL;DR: Neither fish oil supplementation nor aspirin use reduced failure of new arteriovenous fistulae within 12 months of surgery within the FAVOURED study.
Journal ArticleDOI
Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study
Ashley Irish,Gursharan Dogra,Trevor A. Mori,Elaine Beller,Stephanie R Heritier,Carmel M. Hawley,Carmel M. Hawley,Peter G. Kerr,Amanda Robertson,Johan B. Rosman,Peta-Anne Paul-Brent,Melissa Starfield,Kevan R. Polkinghorne,Alan Cass +13 more
TL;DR: This multicentre Australian and New Zealand study has been designed to determine whether the outcome of surgery to create de novo AVF can be improved by the use of aspirin and/or omega-3 fatty acids.
Journal ArticleDOI
A tRial Evaluating Mid Cut-Off Value Membrane Clearance of Albumin and Light Chains in HemoDialysis Patients: A Safety Device Study.
Rathika Krishnasamy,Carmel M. Hawley,Meg Jardine,Matthew A Roberts,Yeoungjee Cho,Muhgeot Wong,Anne Heath,Craig Nelson,Shaundeep Sen,Peter F Mount,Elaine M. Pascoe,Liza A. Vergara,Peta-Anne Paul-Brent,Nigel D Toussaint,David W. Johnson,Colin A. Hutchison +15 more
TL;DR: Regular HD using the MCO dialyzer did not result in a significant fall in serum albumin and there was no improvement in restless legs symptoms, quality of life, 6MWT or MIS scores.
Journal ArticleDOI
Fish oil and aspirin effects on arteriovenous fistula function: Secondary outcomes of the randomised omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) trial.
Andrea K. Viecelli,Andrea K. Viecelli,Kevan R. Polkinghorne,Elaine M. Pascoe,Peta-Anne Paul-Brent,Carmel M. Hawley,Carmel M. Hawley,Carmel M. Hawley,Sunil V. Badve,Sunil V. Badve,Sunil V. Badve,Alan Cass,Lai Seong Hooi,Peter G. Kerr,Trevor A. Mori,Loke Meng Ong,David Voss,David W. Johnson,David W. Johnson,David W. Johnson,Ashley Irish,Ashley Irish +21 more
TL;DR: Although fish oil and low-dose aspirin given for 3 months reduced intervention rates in newly created AVF, they had no significant effects on CVC exposure, AVF usability and time to primary patency loss or access abandonment.
Journal ArticleDOI
The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications
Andrea K. Viecelli,Elaine M. Pascoe,Kevan R. Polkinghorne,Kevan R. Polkinghorne,Carmel M. Hawley,Carmel M. Hawley,Peta-Anne Paul-Brent,Sunil V. Badve,Sunil V. Badve,Alan Cass,Stephane Heritier,Peter G. Kerr,Peter G. Kerr,Trevor A. Mori,Amanda Robertson,Hooi Lai Seong,Ashley Irish,Ashley Irish +17 more
TL;DR: This multicentre international clinical trial was amended to address the clinically relevant question of whether the usability of de novo AVF at 12 months can be improved by the early use of omega-3 PUFAs and to a lesser extent aspirin.